Corrigendum: Ligand-based CAR T-cell: Different strategies to drive T-cells in future new treatments

Alejandro Ramírez-Chacón; Sergi Betriu-Méndez; Ariadna Bartoló-Ibars; Azucena González; Mercè Martí; Manel Juan

doi:10.3389/fimmu.2022.1078003

Corrigendum: Ligand-based CAR T-cell: Different strategies to drive T-cells in future new treatments

Front Immunol. 2022 Nov 21:13:1078003. doi: 10.3389/fimmu.2022.1078003. eCollection 2022.

Authors

Alejandro Ramírez-Chacón^{1

2}, Sergi Betriu-Méndez^{3

4}, Ariadna Bartoló-Ibars^{3

4}, Azucena González^{3

4

5}, Mercè Martí^{1

2}, Manel Juan^{3

4

5}

Affiliations

¹ Immunology Unit, Department of Cellular Biology, Physiology and Immunology, Universitat Autònoma de Barcelona (UAB), Cerdanyola del Vallès, Spain.
² Laboratory of Cellular Immunology, Institute of Biotechnology and Biomedicine (IBB), Cerdanyola del Vallès, Spain.
³ Immunology Department, Hospital Cl´ınic de Barcelona, Centre de Diagnòstic Biomèdic (CDB), Barcelona, Spain.
⁴ Immunology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) -Fundació Clínic per a la Recerca Biomèdica (FCRB) Universitat de Barcelona (UB), Barcelona, Spain.
⁵ Immunology Department, Hospital Sant Joan de Déu, Barcelona, Spain.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2022.932559.].

Keywords: BAR; CAAR; T cells; antigen; chimeric antigen receptor (CAR); ligands; receptor.

Publication types

Published Erratum